Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q2 2016 · 10-Q
Revenue$0.00$0.00— vs Q2 2015 Net Income-$1.33M-$1.33MN/M vs Q2 2015 EPS Diluted$0.00$0.00— vs Q2 2015 Operating Income-$1,330,059N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
derived
ended Jun 30, 2016 · filed Aug 12, 2016 · 43 d after period end